Charles Schwab
ATXI

Charles Schwab’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Charles Schwab’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13
Closed -$87K – 3555
2021
Q1 		$87K Hold
13
– – ﹤0.01% 3390
2020
Q4 		$86K Hold
13
– – ﹤0.01% 3328
2020
Q3 		$156K Hold
13
– – ﹤0.01% 3214
2020
Q2 		$155K Buy
+13
New +$147K ﹤0.01% 3200

Other funds holding ATXI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Charles Schwab's ATXI Position: Q2 2021 in Review

Charles Schwab sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q2 2021, closing a stake of 13 shares — an estimated $87K sold.

Charles Schwab first reported a position in ATXI in Q2 2020 and held it in 4 quarters. The position peaked at $156K in Q3 2020. 24 funds tracked by Wall St. Rank hold ATXI as of Q2 2021.

  • Charles Schwab reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Charles Schwab sold 13 Avenue Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $87K.
  • Charles Schwab first reported a position in Avenue Therapeutics, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
  • Charles Schwab's Avenue Therapeutics, Inc. Common Stock position peaked at $156K in Q3 2020.
  • 24 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.